{"id":"NCT00731198","sponsor":"Changhai Hospital","briefTitle":"Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP)","officialTitle":"Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During ERCP: a Prospective, Multicenter Randomized Controlled Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-08","primaryCompletion":"2009-03","completion":"2009-07","firstPosted":"2008-08-08","resultsPosted":"2009-12-23","lastUpdate":"2010-09-08"},"enrollment":650,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"PREVENTION"},"conditions":["ERCP","Pancreatic Diseases","Bile Duct Diseases"],"interventions":[{"type":"DRUG","name":"Drotaverine hydrochloride","otherNames":["No-spa"]},{"type":"DRUG","name":"Hyoscine-N-butylbromide","otherNames":["Scopolamine Butylbromide"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"The aim of the present study was to evaluate the use of drotaverine hydrochloride versus hyoscine-N-butylbromide in reducing duodenal motility during diagnostic and therapeutic ERCP.","primaryOutcome":{"measure":"The Grades of the Number of Duodenal Contractions","timeFrame":"Intra-procedure","effectByArm":[{"arm":"Experimental","deltaMin":1.13,"sd":0.89},{"arm":"Active Comparator","deltaMin":1.17,"sd":0.82}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":11},"locations":{"siteCount":4,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":319},"commonTop":[]}}